TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary Disease
Brief Summary: This study is not being conducted in the United States.

This study is designed to provide efficacy and safety data for formoterol 10µg twice-a-day (b.i.d.) delivered by the Certihaler in patients with chronic obstructive pulmonary disease (COPD). This study is also designed to compare the efficacy and safety of therapy with formoterol (Certihaler)10µg b.i.d. added to tiotropium (HandiHaler) 18µg once daily (o.d.) compared with tiotropium (HandiHaler) 18µg o.d. monotherapy, and to compare the safety and efficacy of formoterol 10µg b.i.d. (Certihaler) with tiotropium 18µg o.d. (HandiHaler).


Options:
A: Arm Label: indacaterol and glycopyrronium bromide (QVA149); Type: EXPERIMENTAL; Interventions: Drug: indacaterol and glycopyrronium bromide (QVA149) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium | Intervention Type: DRUG; Name: indacaterol and glycopyrronium bromide (QVA149); Assigned to Arm(s): indacaterol and glycopyrronium bromide (QVA149) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium
B: Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): N/A
C: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: QAB149; Type: ACTIVE_COMPARATOR; Interventions: Drug: QAB149 | Arm Label: NVA237; Type: ACTIVE_COMPARATOR; Interventions: Drug: NVA237 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: QAB149; Assigned to Arm(s): QAB149 | Intervention Type: DRUG; Name: NVA237; Assigned to Arm(s): NVA237 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: indacaterol and glycopyrronium (QVA149), Drug: Placebo to fluticasone/salmeterol | Arm Label: fluticasone/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol, Drug: Placebo to indacaterol and glycopyrronium (QVA149) | Intervention Type: DRUG; Name: indacaterol and glycopyrronium (QVA149); Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Placebo to fluticasone/salmeterol; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: fluticasone/salmeterol; Assigned to Arm(s): fluticasone/salmeterol | Intervention Type: DRUG; Name: Placebo to indacaterol and glycopyrronium (QVA149); Assigned to Arm(s): fluticasone/salmeterol

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary Disease
Brief Summary: This study is not being conducted in the United States.

This study is designed to provide efficacy and safety data for formoterol 10µg twice-a-day (b.i.d.) delivered by the Certihaler in patients with chronic obstructive pulmonary disease (COPD). This study is also designed to compare the efficacy and safety of therapy with formoterol (Certihaler)10µg b.i.d. added to tiotropium (HandiHaler) 18µg once daily (o.d.) compared with tiotropium (HandiHaler) 18µg o.d. monotherapy, and to compare the safety and efficacy of formoterol 10µg b.i.d. (Certihaler) with tiotropium 18µg o.d. (HandiHaler).


Options:
A: Arm Label: GFF MDI (PT003); Type: EXPERIMENTAL; Interventions: Drug: GFF MDI (PT003) | Arm Label: Placebo MDI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo MDI | Intervention Type: DRUG; Name: GFF MDI (PT003); Assigned to Arm(s): GFF MDI (PT003) | Intervention Type: DRUG; Name: Placebo MDI; Assigned to Arm(s): Placebo MDI
B: Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): N/A
C: Arm Label: tiotropium + olodaterol low dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium, Drug: olodaterol | Arm Label: tiotropium + olodaterol high dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium, Drug: olodaterol | Arm Label: tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium + olodaterol high dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: olodaterol; Assigned to Arm(s): tiotropium + olodaterol high dose | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium + olodaterol low dose | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium | Intervention Type: DRUG; Name: olodaterol; Assigned to Arm(s): tiotropium + olodaterol low dose
D: Arm Label: GSK573719/GW642444 125/25; Type: EXPERIMENTAL; Interventions: Drug: GSK573719/GW642444 125/25 | Arm Label: GSK573719/GW642444 62.5/25; Type: EXPERIMENTAL; Interventions: Drug: GSK573719/GW642444 62.5/25 | Arm Label: GW642444; Type: EXPERIMENTAL; Interventions: Drug: GW642444 | Arm Label: tiotropium bromide; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium bromide | Intervention Type: DRUG; Name: GSK573719/GW642444 125/25; Assigned to Arm(s): GSK573719/GW642444 125/25 | Intervention Type: DRUG; Name: GSK573719/GW642444 62.5/25; Assigned to Arm(s): GSK573719/GW642444 62.5/25 | Intervention Type: DRUG; Name: GW642444; Assigned to Arm(s): GW642444 | Intervention Type: DRUG; Name: tiotropium bromide; Assigned to Arm(s): tiotropium bromide

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Multicenter Study on the Influence of Colloid vs Crystalloid Volume Resuscitation and of Intensive vs Conventional Insulin Therapy on Outcome in Patients With Severe Sepsis and Septic Shock
Brief Summary: The purpose of this trial is to determine the influence of colloid versus crystalloid volume resuscitation and of intensive vs conventional insulin therapy on morbidity and mortality of patients with severe sepsis and septic shock.


Options:
A: Intervention Type: DRUG; Name: dual-action insulin analog; Assigned to Arm(s): N/A
B: Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: 10% Hemohes® (10% Hydroxyethyl starch); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sterofundin® (Ringer lactate solution); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Actrapid® (Insulin); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Multicenter Study on the Influence of Colloid vs Crystalloid Volume Resuscitation and of Intensive vs Conventional Insulin Therapy on Outcome in Patients With Severe Sepsis and Septic Shock
Brief Summary: The purpose of this trial is to determine the influence of colloid versus crystalloid volume resuscitation and of intensive vs conventional insulin therapy on morbidity and mortality of patients with severe sepsis and septic shock.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crystalloids | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Colloids | Intervention Type: DRUG; Name: Crystalloids; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Colloids; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Crystalloids; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Colloids; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: 10% Hemohes® (10% Hydroxyethyl starch); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sterofundin® (Ringer lactate solution); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Actrapid® (Insulin); Assigned to Arm(s): N/A
C: Arm Label: 7.5% hypertonic saline/6% dextran (HSD); Type: EXPERIMENTAL; Interventions: Drug: 7.5% Hypertonic Saline in 6% Dextran-70 (HSD) | Arm Label: 7.5% hypertonic saline (HS); Type: EXPERIMENTAL; Interventions: Drug: 7.5% Hypertonic Saline (HS) | Arm Label: 0.9% normal saline (NS); Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Normal Saline (NS) | Intervention Type: DRUG; Name: 7.5% Hypertonic Saline in 6% Dextran-70 (HSD); Assigned to Arm(s): 7.5% hypertonic saline/6% dextran (HSD) | Intervention Type: DRUG; Name: 7.5% Hypertonic Saline (HS); Assigned to Arm(s): 7.5% hypertonic saline (HS) | Intervention Type: DRUG; Name: 0.9% Normal Saline (NS); Assigned to Arm(s): 0.9% normal saline (NS)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 7.5% hypertonic saline/6% Dextran-70 (HSD) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: 7.5% hypertonic saline (HS) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% normal saline | Intervention Type: DRUG; Name: 7.5% hypertonic saline/6% Dextran-70 (HSD); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 7.5% hypertonic saline (HS); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: 0.9% normal saline; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Multicenter Study on the Influence of Colloid vs Crystalloid Volume Resuscitation and of Intensive vs Conventional Insulin Therapy on Outcome in Patients With Severe Sepsis and Septic Shock
Brief Summary: The purpose of this trial is to determine the influence of colloid versus crystalloid volume resuscitation and of intensive vs conventional insulin therapy on morbidity and mortality of patients with severe sepsis and septic shock.


Options:
A: Intervention Type: DRUG; Name: 10% Hemohes® (10% Hydroxyethyl starch); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sterofundin® (Ringer lactate solution); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Actrapid® (Insulin); Assigned to Arm(s): N/A
B: Arm Label: HES 130/0.4; Type: EXPERIMENTAL; Interventions: Drug: 6% Hydroxyethyl starch 130/0.4 | Arm Label: Ringer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringers acetate | Intervention Type: DRUG; Name: 6% Hydroxyethyl starch 130/0.4; Assigned to Arm(s): HES 130/0.4 | Intervention Type: DRUG; Name: Ringers acetate; Assigned to Arm(s): Ringer acetate
C: Arm Label: Hydroxy-ethyl starch; Type: EXPERIMENTAL; Interventions: Drug: 6% Hydroxy-ethyl starch (130/0.4) | Arm Label: Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: 6% Hydroxy-ethyl starch (130/0.4); Assigned to Arm(s): Hydroxy-ethyl starch | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline
D: Arm Label: Voluven® Arm; Type: EXPERIMENTAL; Interventions: Drug: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®" | Arm Label: 0.9 % NaCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9 % NaCl | Intervention Type: DRUG; Name: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®"; Assigned to Arm(s): Voluven® Arm | Intervention Type: DRUG; Name: 0.9 % NaCl; Assigned to Arm(s): 0.9 % NaCl

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Chronic Ventilatory Support Improve the Outcomes of Rehabilitation in Hypercapnic COPD Patients?
Brief Summary: The purpose of this study is to investigate whether noninvasive ventilation by nose mask during the night has additional benefits next to pulmonary rehabilitation in patients with severe hypercapnic COPD.


Options:
A: Intervention Type: DEVICE; Name: Noninvasive positive pressure ventilation; Assigned to Arm(s): N/A
B: Arm Label: Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium/Formoterol | Arm Label: Placebo to Aclidinium/Formoterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium/Formoterol; Assigned to Arm(s): Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo to Aclidinium/Formoterol
C: Arm Label: Home-base Pulm Rehab w/ Health Coaching; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home-base Pulmonary Rehab with Health Coaching | Arm Label: Control/Wait; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home-base Pulmonary Rehab with Health Coaching | Intervention Type: BEHAVIORAL; Name: Home-base Pulmonary Rehab with Health Coaching; Assigned to Arm(s): Control/Wait, Home-base Pulm Rehab w/ Health Coaching
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: tiotropium; Type: EXPERIMENTAL; Interventions: Drug: tiotropium | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Chronic Ventilatory Support Improve the Outcomes of Rehabilitation in Hypercapnic COPD Patients?
Brief Summary: The purpose of this study is to investigate whether noninvasive ventilation by nose mask during the night has additional benefits next to pulmonary rehabilitation in patients with severe hypercapnic COPD.


Options:
A: Arm Label: NPPV group; Type: EXPERIMENTAL; Interventions: Device: ventilators designed for non invasive ventilation | Arm Label: control gorup; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ventilators designed for non invasive ventilation; Assigned to Arm(s): NPPV group
B: Arm Label: LTNIV group; Type: EXPERIMENTAL; Interventions: Device: LTNIV | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: LTNIV; Assigned to Arm(s): LTNIV group
C: Arm Label: Active Treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous Positive Airway Pressure (CPAP) Treatment | Arm Label: Sham/Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham CPAP device - CPAP device with pressure delivered <1 cm H20 | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP) Treatment; Assigned to Arm(s): Active Treatment | Intervention Type: DEVICE; Name: Sham CPAP device - CPAP device with pressure delivered <1 cm H20; Assigned to Arm(s): Sham/Placebo Treatment
D: Intervention Type: DEVICE; Name: Noninvasive positive pressure ventilation; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial
Brief Summary: A number of major clinical trials have demonstrated the clinical benefits of lowering blood pressure and have indicated that a majority of patients with hypertension will require more than one drug to achieve optimal blood pressure control.

There is little data showing which antihypertensive combination best protects patients from cardiovascular events and which best achieves the target blood pressure with the fewest adverse events.

The COPE trial is planned to investigate, in patients with hypertension, which combination of the antihypertensive drugs, angiotensin receptor blockers, β-blockers or thiazide diuretics in addition to a long-acting calcium antagonist, benidipine hydrochloride, is superior to achieve the targeted blood pressure and prevent cardiovascular events with the fewest adverse drug effects.


Options:
A: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
C: Arm Label: Chlorthalidone plus amiloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorthalidone plus amiloride | Arm Label: losartan; Type: EXPERIMENTAL; Interventions: Drug: losartan | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): losartan | Intervention Type: DRUG; Name: Chlorthalidone plus amiloride; Assigned to Arm(s): Chlorthalidone plus amiloride
D: Arm Label: angiotensin receptor blockers; Type: ACTIVE_COMPARATOR; Interventions: Drug: Angiotensin receptor blockers | Arm Label: β-blockers; Type: ACTIVE_COMPARATOR; Interventions: Drug: β-blockers | Arm Label: thiazide diuretics; Type: ACTIVE_COMPARATOR; Interventions: Drug: thiazide diuretics | Intervention Type: DRUG; Name: Angiotensin receptor blockers; Assigned to Arm(s): angiotensin receptor blockers | Intervention Type: DRUG; Name: β-blockers; Assigned to Arm(s): β-blockers | Intervention Type: DRUG; Name: thiazide diuretics; Assigned to Arm(s): thiazide diuretics

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Effectiveness of a Protein Pulse-Feeding Pattern in Elderly Patients
Brief Summary: The researchers tested the hypothesis that a protein pulse-feeding pattern was more efficient in improving muscle mass and immune functions than was a protein spread-feeding pattern, after 45 days, in elderly malnourished patients.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein pulse-feeding | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Spread diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein pulse-feeding; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Spread diet; Assigned to Arm(s): 2
B: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment as usual | Arm Label: Received nutrition supplement as needed; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Nutritional supplement, Other: Treatment as usual | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutritional supplement; Assigned to Arm(s): Received nutrition supplement as needed | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): Control, Received nutrition supplement as needed
C: Arm Label: Protein enriched yoghurt drink and bread; Type: EXPERIMENTAL; Interventions: Other: Protein enriched yoghurt drink and bread | Arm Label: Regular yoghurt drink and bread; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Protein enriched yoghurt drink and bread; Assigned to Arm(s): Protein enriched yoghurt drink and bread
D: Arm Label: Ready to drink flavored beverage; Type: PLACEBO_COMPARATOR; Interventions: Other: Ready to Drink Flavored Beverage | Arm Label: Ready to drink flavored beverage w/ AN 777; Type: EXPERIMENTAL; Interventions: Other: Ready to drink flavored beverage w/ AN 777 | Intervention Type: OTHER; Name: Ready to Drink Flavored Beverage; Assigned to Arm(s): Ready to drink flavored beverage | Intervention Type: OTHER; Name: Ready to drink flavored beverage w/ AN 777; Assigned to Arm(s): Ready to drink flavored beverage w/ AN 777

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized Multicentric Trial Comparing Amoxicillin/Clavulanate Potassium Therapy to Appendectomy for Acute Non Complicated Appendicitis
Brief Summary: The purpose of the study is to demonstrate that antibiotic therapy is as safe and effective as appendectomy for the treatment of acute non complicated appendicitis. Two hundred fifty patients will be included in a prospective multicentric randomized trial. The primary endpoint is the rate of intra abdominal infections in both therapeutic strategies. Other criteria will be studied including duration of hospital stay and absence from work during a follow up period of one year, parietal and abdominal complications and recurrent appendicitis after antibiotic therapy.


Options:
A: Arm Label: Diagnostic imaging; Type: EXPERIMENTAL; Interventions: Procedure: Diagnostic imaging | Arm Label: Repeat examination after observation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Diagnostic imaging | Intervention Type: PROCEDURE; Name: Diagnostic imaging; Assigned to Arm(s): Diagnostic imaging, Repeat examination after observation
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: appendectomy | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: amoxicillin/clavulanate potassium | Intervention Type: DRUG; Name: amoxicillin/clavulanate potassium; Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: appendectomy; Assigned to Arm(s): A
C: Arm Label: Low-dose CT; Type: EXPERIMENTAL; Interventions: Radiation: Diagnostic CT | Arm Label: Standard-dose CT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Diagnostic CT | Intervention Type: RADIATION; Name: Diagnostic CT; Assigned to Arm(s): Low-dose CT | Intervention Type: RADIATION; Name: Diagnostic CT; Assigned to Arm(s): Standard-dose CT
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Omnipaque | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Omnipaque | Intervention Type: OTHER; Name: Omnipaque; Assigned to Arm(s): 1, 2

Answer: B